EyeGene
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
EyeGene is a South Korean biotech venture that develops experimental vaccines and gene therapies, treatments that work by introducing genetic material into the body to fight disease.
Its pipeline targets hard-to-treat conditions including age-related macular degeneration, diabetic retinopathy, and rare inherited retinal diseases, as well as infectious-disease vaccines. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company is advancing two core technology platforms: messenger-RNA-based vaccines and AAV (adeno-associated virus) gene therapies, while also co-developing near-term commercial products such as a meningococcal vaccine and a recombinant botulinum toxin to help fund its research.
Summary is AI-generated and may contain errors · figures from DART filings
The company is developing its next-generation coronavirus mRNA vaccine through a co-development consortium formed with five domestic and international partners.
EyeGene in five facts
What does EyeGene do?
EyeGene is a South Korean biotech venture that develops experimental vaccines and gene therapies, treatments that work by introducing genetic material into the body to fight disease.
Where is EyeGene listed and in which sector?
EyeGene (Korean name: 아이진) trades under KRX code 185490 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is EyeGene?
Its market capitalisation was US$63.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were EyeGene's latest annual revenue and operating profit?
For fiscal year 2025, EyeGene reported revenue of US$2.7M, an operating loss of US$7.4M and a net loss of US$14.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 6.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.